AKT1 and neoplasm: Phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) inhibitors combined with OVs offers a promising strategy to enhance tumor susceptibility to oncolysis and modulate TME for better outcomes.